Rare diseases Marathon sells Duchenne drug to PTC PTC says it will make changes to the price after abandoned launch last month.
News US drug revenues far exceed R&D spend - report Analysis questions industry's rationale for high US prices.
News Concordia and Actavis face UK pricing probe Firms colluded to hike prices, says competition watchdog.
News J&J: drug price rises below 10% since 2012 Janssen unit responds to criticism from president Trump over pricing.
News Pfizer under investigation over links with charities US authorities probing several other drugmakers amid pricing row.
News Pharma must slash rare disease drug prices - patient organis... More rare disease drugs must also be approved, says EURORDIS.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
